Celularity Revenue and Competitors

Claim your profile

Warren, NJ USA

Location

$400M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Celularity's estimated annual revenue is currently $76.2M per year.(i)
  • Celularity received $250.0M in venture funding in February 2018.
  • Celularity's estimated revenue per employee is $217,000
  • Celularity's total funding is $400M.

Employee Data

  • Celularity has 351 Employees.(i)
  • Celularity grew their employee count by 24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$34.3M215-8%N/AN/A

POSTPARTUM PLACENTA: THE FOUNDATION OF OUR SCIENCE - Celularity scientists were the first to recognize the human placenta as an untapped resource for innovation, one which is the basis of Celularity innovations in immuno-oncology, hematology, and regenerative medicine. Our seminal discovery of unique stem, progenitor, and immune cells from the placenta is the foundation of our dominating intellectual property position. With proprietary platform technology and operational expertise to harness the power of this remarkable organ, we developed a deep therapeutic pipeline across a broad range of indications. AMPLIFYING THE BODYS ABILITY TO REGENERATE - Celularity combines innovative assets and research in cell therapy, functional regeneration, and biosourcing to develop leading therapeutic products and services that treat serious, life-threatening diseases. We are harnessing the unique cells and biomaterials from the postpartum placenta to provide therapies that amplify the body's ability to fight disease, heal, and regenerate itself. For more information visit our website at www.celularity.com

keywords:N/A

$400M

Total Funding

351

Number of Employees

$76.2M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Celularity News

2022-03-22 - Celularity to Present at Oppenheimer 32nd Annual Healthcare ...

Celularity Inc. ... These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity...

2022-03-22 - Celularity Reports Fourth Quarter and Full Year 2021 ...

Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address...

2020-04-02 - Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19

Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19. The company, which has raised at least $290 million to date ...

2019-09-08 - How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell ...

A spinout of Celgene, Celularity made big news in February 2018, when it raised $250 million to accelerate development of its stem cell ...

2019-04-11 - Celularity Enters Lease to Develop Advanced Cell ...

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$159.9M396N/AN/A
#2
$184.9M419-7%N/A
#3
$35M43529%N/A
#4
$135.7M4365%N/A
#5
$7.5M43759%N/A

Celularity Funding

DateAmountRoundLead InvestorsReference
2018-02-16$250.0MUndisclosedMultipleArticle